Quinazolinone compounds as anticancer agents

US7939539B2 · kind B2 · utility

Assignee

• Novartis Vaccines and Diagnostics, Inc. · US

Inventors

• Weibo Wang · Moraga, US
• Liana Lagniton · Berkeley, US
• Ryan Constantine · Oakland, US
• Manoj C. Desai · Pleasant Hill, US

Key dates

• Filing date: Nov 24, 2004
• Grant date: May 10, 2011
• Expiry date: Nov 13, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D239/90
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Quinazolinone compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the quinazolinone compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the quinazolinone compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.